AI Summary & Key Takeaways
AI InsightThese results show that low MPO levels in MS patients have an important role in the pathogenesis of MS.
📌 3 Key Takeaways
Abstract
Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system characterized by inflammation, demyelination, and neurodegeneration. It may lead to physical disability, acute neurological, and cognitive problems. The specific etiology of MS has not been clearly defined to date. One of the key factors that play a role in the pathogenesis of MS is oxidative stress, which increases inflammation and neurodegeneration. Myeloperoxidase (MPO) is one of the enzymes secreted by activated inflammatory cells and is produced by monocytes, macrophages, microglia, and neutrophils. At the same time, myeloperoxidase is one of the components of oxidative stress. MPO has been investigated many times in MS patients, but peripheral blood levels of MPO have been studied very few times. This study investigated serum MPO levels in MS, and the relationship of these levels with patients' age, disease duration, prognosis, annualized relapse rate (ARR), EDSS scores, and disease-modifying drug therapies (DMT) used. The study included 50 MS patients and 50 healthy controls, and their demographic and clinical characteristics were determined. Serum MPO levels were significantly lower in MS patients than in the healthy control group (p=0034). No significant correlation was found between MPO levels and patients' age, EDSS scores, disease year, DMTs used, and disease progression (p>0.05). These results show that low MPO levels in MS patients have an important role in the pathogenesis of MS. There is a need for further studies on this subject.